The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Liposome Assisted Drug Delivery Market Research Report 2025
Synopsis
Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only.
The global Liposome Assisted Drug Delivery market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Liposome Assisted Drug Delivery, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposome Assisted Drug Delivery.
Report Scope
The Liposome Assisted Drug Delivery market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Liposome Assisted Drug Delivery market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Liposome Assisted Drug Delivery companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gilead Sciences
Pacira
Sun Pharmaceutical
Johnson & Johnson
Luye Pharma
Sigma-Tau Group
Ipsen (Onivyde)
CSPC
Teva Pharmaceutical
Novartis
Fudan-Zhangjiang
Segment by Type
Liposomal Doxorubicin
Liposomal Amphoteracin B
Liposomal Paclitaxel
Others
Segment by Application
Fungal Infection Therapy
Cancer & Tumor Therapy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Liposome Assisted Drug Delivery companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only.
The global Liposome Assisted Drug Delivery market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Liposome Assisted Drug Delivery, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposome Assisted Drug Delivery.
Report Scope
The Liposome Assisted Drug Delivery market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Liposome Assisted Drug Delivery market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Liposome Assisted Drug Delivery companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gilead Sciences
Pacira
Sun Pharmaceutical
Johnson & Johnson
Luye Pharma
Sigma-Tau Group
Ipsen (Onivyde)
CSPC
Teva Pharmaceutical
Novartis
Fudan-Zhangjiang
Segment by Type
Liposomal Doxorubicin
Liposomal Amphoteracin B
Liposomal Paclitaxel
Others
Segment by Application
Fungal Infection Therapy
Cancer & Tumor Therapy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Liposome Assisted Drug Delivery companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Liposome Assisted Drug Delivery Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Liposomal Doxorubicin
1.2.3 Liposomal Amphoteracin B
1.2.4 Liposomal Paclitaxel
1.2.5 Others
1.3 Market by Application
1.3.1 Global Liposome Assisted Drug Delivery Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Fungal Infection Therapy
1.3.3 Cancer & Tumor Therapy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Liposome Assisted Drug Delivery Market Perspective (2019-2030)
2.2 Liposome Assisted Drug Delivery Growth Trends by Region
2.2.1 Global Liposome Assisted Drug Delivery Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Liposome Assisted Drug Delivery Historic Market Size by Region (2019-2024)
2.2.3 Liposome Assisted Drug Delivery Forecasted Market Size by Region (2025-2030)
2.3 Liposome Assisted Drug Delivery Market Dynamics
2.3.1 Liposome Assisted Drug Delivery Industry Trends
2.3.2 Liposome Assisted Drug Delivery Market Drivers
2.3.3 Liposome Assisted Drug Delivery Market Challenges
2.3.4 Liposome Assisted Drug Delivery Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Liposome Assisted Drug Delivery Players by Revenue
3.1.1 Global Top Liposome Assisted Drug Delivery Players by Revenue (2019-2024)
3.1.2 Global Liposome Assisted Drug Delivery Revenue Market Share by Players (2019-2024)
3.2 Global Liposome Assisted Drug Delivery Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Liposome Assisted Drug Delivery Revenue
3.4 Global Liposome Assisted Drug Delivery Market Concentration Ratio
3.4.1 Global Liposome Assisted Drug Delivery Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Liposome Assisted Drug Delivery Revenue in 2023
3.5 Liposome Assisted Drug Delivery Key Players Head office and Area Served
3.6 Key Players Liposome Assisted Drug Delivery Product Solution and Service
3.7 Date of Enter into Liposome Assisted Drug Delivery Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Liposome Assisted Drug Delivery Breakdown Data by Type
4.1 Global Liposome Assisted Drug Delivery Historic Market Size by Type (2019-2024)
4.2 Global Liposome Assisted Drug Delivery Forecasted Market Size by Type (2025-2030)
5 Liposome Assisted Drug Delivery Breakdown Data by Application
5.1 Global Liposome Assisted Drug Delivery Historic Market Size by Application (2019-2024)
5.2 Global Liposome Assisted Drug Delivery Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Liposome Assisted Drug Delivery Market Size (2019-2030)
6.2 North America Liposome Assisted Drug Delivery Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Liposome Assisted Drug Delivery Market Size by Country (2019-2024)
6.4 North America Liposome Assisted Drug Delivery Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Liposome Assisted Drug Delivery Market Size (2019-2030)
7.2 Europe Liposome Assisted Drug Delivery Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Liposome Assisted Drug Delivery Market Size by Country (2019-2024)
7.4 Europe Liposome Assisted Drug Delivery Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Liposome Assisted Drug Delivery Market Size (2019-2030)
8.2 Asia-Pacific Liposome Assisted Drug Delivery Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Liposome Assisted Drug Delivery Market Size by Region (2019-2024)
8.4 Asia-Pacific Liposome Assisted Drug Delivery Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Liposome Assisted Drug Delivery Market Size (2019-2030)
9.2 Latin America Liposome Assisted Drug Delivery Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Liposome Assisted Drug Delivery Market Size by Country (2019-2024)
9.4 Latin America Liposome Assisted Drug Delivery Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Liposome Assisted Drug Delivery Market Size (2019-2030)
10.2 Middle East & Africa Liposome Assisted Drug Delivery Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Liposome Assisted Drug Delivery Market Size by Country (2019-2024)
10.4 Middle East & Africa Liposome Assisted Drug Delivery Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Gilead Sciences
11.1.1 Gilead Sciences Company Detail
11.1.2 Gilead Sciences Business Overview
11.1.3 Gilead Sciences Liposome Assisted Drug Delivery Introduction
11.1.4 Gilead Sciences Revenue in Liposome Assisted Drug Delivery Business (2019-2024)
11.1.5 Gilead Sciences Recent Development
11.2 Pacira
11.2.1 Pacira Company Detail
11.2.2 Pacira Business Overview
11.2.3 Pacira Liposome Assisted Drug Delivery Introduction
11.2.4 Pacira Revenue in Liposome Assisted Drug Delivery Business (2019-2024)
11.2.5 Pacira Recent Development
11.3 Sun Pharmaceutical
11.3.1 Sun Pharmaceutical Company Detail
11.3.2 Sun Pharmaceutical Business Overview
11.3.3 Sun Pharmaceutical Liposome Assisted Drug Delivery Introduction
11.3.4 Sun Pharmaceutical Revenue in Liposome Assisted Drug Delivery Business (2019-2024)
11.3.5 Sun Pharmaceutical Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Liposome Assisted Drug Delivery Introduction
11.4.4 Johnson & Johnson Revenue in Liposome Assisted Drug Delivery Business (2019-2024)
11.4.5 Johnson & Johnson Recent Development
11.5 Luye Pharma
11.5.1 Luye Pharma Company Detail
11.5.2 Luye Pharma Business Overview
11.5.3 Luye Pharma Liposome Assisted Drug Delivery Introduction
11.5.4 Luye Pharma Revenue in Liposome Assisted Drug Delivery Business (2019-2024)
11.5.5 Luye Pharma Recent Development
11.6 Sigma-Tau Group
11.6.1 Sigma-Tau Group Company Detail
11.6.2 Sigma-Tau Group Business Overview
11.6.3 Sigma-Tau Group Liposome Assisted Drug Delivery Introduction
11.6.4 Sigma-Tau Group Revenue in Liposome Assisted Drug Delivery Business (2019-2024)
11.6.5 Sigma-Tau Group Recent Development
11.7 Ipsen (Onivyde)
11.7.1 Ipsen (Onivyde) Company Detail
11.7.2 Ipsen (Onivyde) Business Overview
11.7.3 Ipsen (Onivyde) Liposome Assisted Drug Delivery Introduction
11.7.4 Ipsen (Onivyde) Revenue in Liposome Assisted Drug Delivery Business (2019-2024)
11.7.5 Ipsen (Onivyde) Recent Development
11.8 CSPC
11.8.1 CSPC Company Detail
11.8.2 CSPC Business Overview
11.8.3 CSPC Liposome Assisted Drug Delivery Introduction
11.8.4 CSPC Revenue in Liposome Assisted Drug Delivery Business (2019-2024)
11.8.5 CSPC Recent Development
11.9 Teva Pharmaceutical
11.9.1 Teva Pharmaceutical Company Detail
11.9.2 Teva Pharmaceutical Business Overview
11.9.3 Teva Pharmaceutical Liposome Assisted Drug Delivery Introduction
11.9.4 Teva Pharmaceutical Revenue in Liposome Assisted Drug Delivery Business (2019-2024)
11.9.5 Teva Pharmaceutical Recent Development
11.10 Novartis
11.10.1 Novartis Company Detail
11.10.2 Novartis Business Overview
11.10.3 Novartis Liposome Assisted Drug Delivery Introduction
11.10.4 Novartis Revenue in Liposome Assisted Drug Delivery Business (2019-2024)
11.10.5 Novartis Recent Development
11.11 Fudan-Zhangjiang
11.11.1 Fudan-Zhangjiang Company Detail
11.11.2 Fudan-Zhangjiang Business Overview
11.11.3 Fudan-Zhangjiang Liposome Assisted Drug Delivery Introduction
11.11.4 Fudan-Zhangjiang Revenue in Liposome Assisted Drug Delivery Business (2019-2024)
11.11.5 Fudan-Zhangjiang Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Liposome Assisted Drug Delivery Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Liposomal Doxorubicin
Table 3. Key Players of Liposomal Amphoteracin B
Table 4. Key Players of Liposomal Paclitaxel
Table 5. Key Players of Others
Table 6. Global Liposome Assisted Drug Delivery Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Liposome Assisted Drug Delivery Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Liposome Assisted Drug Delivery Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Liposome Assisted Drug Delivery Market Share by Region (2019-2024)
Table 10. Global Liposome Assisted Drug Delivery Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Liposome Assisted Drug Delivery Market Share by Region (2025-2030)
Table 12. Liposome Assisted Drug Delivery Market Trends
Table 13. Liposome Assisted Drug Delivery Market Drivers
Table 14. Liposome Assisted Drug Delivery Market Challenges
Table 15. Liposome Assisted Drug Delivery Market Restraints
Table 16. Global Liposome Assisted Drug Delivery Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Liposome Assisted Drug Delivery Market Share by Players (2019-2024)
Table 18. Global Top Liposome Assisted Drug Delivery Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposome Assisted Drug Delivery as of 2023)
Table 19. Ranking of Global Top Liposome Assisted Drug Delivery Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Liposome Assisted Drug Delivery Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Liposome Assisted Drug Delivery Product Solution and Service
Table 23. Date of Enter into Liposome Assisted Drug Delivery Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Liposome Assisted Drug Delivery Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Liposome Assisted Drug Delivery Revenue Market Share by Type (2019-2024)
Table 27. Global Liposome Assisted Drug Delivery Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Liposome Assisted Drug Delivery Revenue Market Share by Type (2025-2030)
Table 29. Global Liposome Assisted Drug Delivery Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Liposome Assisted Drug Delivery Revenue Market Share by Application (2019-2024)
Table 31. Global Liposome Assisted Drug Delivery Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Liposome Assisted Drug Delivery Revenue Market Share by Application (2025-2030)
Table 33. North America Liposome Assisted Drug Delivery Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Liposome Assisted Drug Delivery Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Liposome Assisted Drug Delivery Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Liposome Assisted Drug Delivery Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Liposome Assisted Drug Delivery Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Liposome Assisted Drug Delivery Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Liposome Assisted Drug Delivery Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Liposome Assisted Drug Delivery Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Liposome Assisted Drug Delivery Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Liposome Assisted Drug Delivery Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Liposome Assisted Drug Delivery Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Liposome Assisted Drug Delivery Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Liposome Assisted Drug Delivery Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Liposome Assisted Drug Delivery Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Liposome Assisted Drug Delivery Market Size by Country (2025-2030) & (US$ Million)
Table 48. Gilead Sciences Company Detail
Table 49. Gilead Sciences Business Overview
Table 50. Gilead Sciences Liposome Assisted Drug Delivery Product
Table 51. Gilead Sciences Revenue in Liposome Assisted Drug Delivery Business (2019-2024) & (US$ Million)
Table 52. Gilead Sciences Recent Development
Table 53. Pacira Company Detail
Table 54. Pacira Business Overview
Table 55. Pacira Liposome Assisted Drug Delivery Product
Table 56. Pacira Revenue in Liposome Assisted Drug Delivery Business (2019-2024) & (US$ Million)
Table 57. Pacira Recent Development
Table 58. Sun Pharmaceutical Company Detail
Table 59. Sun Pharmaceutical Business Overview
Table 60. Sun Pharmaceutical Liposome Assisted Drug Delivery Product
Table 61. Sun Pharmaceutical Revenue in Liposome Assisted Drug Delivery Business (2019-2024) & (US$ Million)
Table 62. Sun Pharmaceutical Recent Development
Table 63. Johnson & Johnson Company Detail
Table 64. Johnson & Johnson Business Overview
Table 65. Johnson & Johnson Liposome Assisted Drug Delivery Product
Table 66. Johnson & Johnson Revenue in Liposome Assisted Drug Delivery Business (2019-2024) & (US$ Million)
Table 67. Johnson & Johnson Recent Development
Table 68. Luye Pharma Company Detail
Table 69. Luye Pharma Business Overview
Table 70. Luye Pharma Liposome Assisted Drug Delivery Product
Table 71. Luye Pharma Revenue in Liposome Assisted Drug Delivery Business (2019-2024) & (US$ Million)
Table 72. Luye Pharma Recent Development
Table 73. Sigma-Tau Group Company Detail
Table 74. Sigma-Tau Group Business Overview
Table 75. Sigma-Tau Group Liposome Assisted Drug Delivery Product
Table 76. Sigma-Tau Group Revenue in Liposome Assisted Drug Delivery Business (2019-2024) & (US$ Million)
Table 77. Sigma-Tau Group Recent Development
Table 78. Ipsen (Onivyde) Company Detail
Table 79. Ipsen (Onivyde) Business Overview
Table 80. Ipsen (Onivyde) Liposome Assisted Drug Delivery Product
Table 81. Ipsen (Onivyde) Revenue in Liposome Assisted Drug Delivery Business (2019-2024) & (US$ Million)
Table 82. Ipsen (Onivyde) Recent Development
Table 83. CSPC Company Detail
Table 84. CSPC Business Overview
Table 85. CSPC Liposome Assisted Drug Delivery Product
Table 86. CSPC Revenue in Liposome Assisted Drug Delivery Business (2019-2024) & (US$ Million)
Table 87. CSPC Recent Development
Table 88. Teva Pharmaceutical Company Detail
Table 89. Teva Pharmaceutical Business Overview
Table 90. Teva Pharmaceutical Liposome Assisted Drug Delivery Product
Table 91. Teva Pharmaceutical Revenue in Liposome Assisted Drug Delivery Business (2019-2024) & (US$ Million)
Table 92. Teva Pharmaceutical Recent Development
Table 93. Novartis Company Detail
Table 94. Novartis Business Overview
Table 95. Novartis Liposome Assisted Drug Delivery Product
Table 96. Novartis Revenue in Liposome Assisted Drug Delivery Business (2019-2024) & (US$ Million)
Table 97. Novartis Recent Development
Table 98. Fudan-Zhangjiang Company Detail
Table 99. Fudan-Zhangjiang Business Overview
Table 100. Fudan-Zhangjiang Liposome Assisted Drug Delivery Product
Table 101. Fudan-Zhangjiang Revenue in Liposome Assisted Drug Delivery Business (2019-2024) & (US$ Million)
Table 102. Fudan-Zhangjiang Recent Development
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Liposome Assisted Drug Delivery Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Liposome Assisted Drug Delivery Market Share by Type: 2023 VS 2030
Figure 3. Liposomal Doxorubicin Features
Figure 4. Liposomal Amphoteracin B Features
Figure 5. Liposomal Paclitaxel Features
Figure 6. Others Features
Figure 7. Global Liposome Assisted Drug Delivery Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Liposome Assisted Drug Delivery Market Share by Application: 2023 VS 2030
Figure 9. Fungal Infection Therapy Case Studies
Figure 10. Cancer & Tumor Therapy Case Studies
Figure 11. Others Case Studies
Figure 12. Liposome Assisted Drug Delivery Report Years Considered
Figure 13. Global Liposome Assisted Drug Delivery Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Liposome Assisted Drug Delivery Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Liposome Assisted Drug Delivery Market Share by Region: 2023 VS 2030
Figure 16. Global Liposome Assisted Drug Delivery Market Share by Players in 2023
Figure 17. Global Top Liposome Assisted Drug Delivery Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposome Assisted Drug Delivery as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Liposome Assisted Drug Delivery Revenue in 2023
Figure 19. North America Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Liposome Assisted Drug Delivery Market Share by Country (2019-2030)
Figure 21. United States Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Liposome Assisted Drug Delivery Market Share by Country (2019-2030)
Figure 25. Germany Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Liposome Assisted Drug Delivery Market Share by Region (2019-2030)
Figure 33. China Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Liposome Assisted Drug Delivery Market Share by Country (2019-2030)
Figure 41. Mexico Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Liposome Assisted Drug Delivery Market Share by Country (2019-2030)
Figure 45. Turkey Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Liposome Assisted Drug Delivery Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Gilead Sciences Revenue Growth Rate in Liposome Assisted Drug Delivery Business (2019-2024)
Figure 48. Pacira Revenue Growth Rate in Liposome Assisted Drug Delivery Business (2019-2024)
Figure 49. Sun Pharmaceutical Revenue Growth Rate in Liposome Assisted Drug Delivery Business (2019-2024)
Figure 50. Johnson & Johnson Revenue Growth Rate in Liposome Assisted Drug Delivery Business (2019-2024)
Figure 51. Luye Pharma Revenue Growth Rate in Liposome Assisted Drug Delivery Business (2019-2024)
Figure 52. Sigma-Tau Group Revenue Growth Rate in Liposome Assisted Drug Delivery Business (2019-2024)
Figure 53. Ipsen (Onivyde) Revenue Growth Rate in Liposome Assisted Drug Delivery Business (2019-2024)
Figure 54. CSPC Revenue Growth Rate in Liposome Assisted Drug Delivery Business (2019-2024)
Figure 55. Teva Pharmaceutical Revenue Growth Rate in Liposome Assisted Drug Delivery Business (2019-2024)
Figure 56. Novartis Revenue Growth Rate in Liposome Assisted Drug Delivery Business (2019-2024)
Figure 57. Fudan-Zhangjiang Revenue Growth Rate in Liposome Assisted Drug Delivery Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
